Lethal Congenital Contracture Syndrome 2
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Insulin-like Growth Factor Binding Protein-3 expression in the human corneal epithelium.
|
17709104 |
2007 |
Lethal Congenital Contracture Syndrome 2
|
0.600 |
GermlineCausalMutation
|
disease |
ORPHANET |
Lethal congenital contractural syndrome type 2 (LCCS2) is caused by a mutation in ERBB3 (Her3), a modulator of the phosphatidylinositol-3-kinaseAkt pathway.
|
17701904 |
2007 |
Lethal Congenital Contracture Syndrome 2
|
0.600 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Regulation of neuregulin/ErbB signaling by contractile activity in skeletal muscle.
|
12519750 |
2003 |
Lethal Congenital Contracture Syndrome 2
|
0.600 |
Biomarker
|
disease |
CTD_human |
|
|
|
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Human epidermal growth factor receptor HER3 (ErbB3), especially in association with its relative HER2 (ErbB2), is known as a key oncogene in breast tumour biology.
|
30367623 |
2018 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis.
|
28114269 |
2017 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
In both cell lines and primary patient samples, we observed consistent expression patterns of these biomarkers varies by cancer indication, such that ERBB3 and CDKN1B expression are relatively high in breast tumors while EGFR expression is relatively high in other indications.
|
27035903 |
2016 |
Mammary Neoplasms
|
0.500 |
GeneticVariation
|
group |
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The growth factor heregulin (HRG), a ligand of ErbB3 and ErbB4 receptors, contributes to breast cancer development and the promotion of metastatic disease, and its expression in breast tumors has been associated with poor clinical outcome and resistance to therapy.
|
27185877 |
2016 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Specific knockdown of mouse erbB3 dramatically inhibited proliferation of the mammary tumor cell lines-derived from the transgenic mice.
|
26261492 |
2015 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Interestingly, the expression level of pHER2 significantly correlated with the expression levels of HER2 and HER3 in HER2-positive breast tumors.
|
23749689 |
2015 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Accumulating evidences indicate that miR-205-5p is significantly downregulated in breast tumors compared with normal breast tissue and acts as a tumor suppressor directly targeting oncogenes such as Zeb1 and ErbB3.
|
26181203 |
2015 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The aim of this study was to evaluate the prognostic and predictive value of HER3, PTEN and phosphorylated HER2 (p-HER2) expression in primary breast tumors of patients treated with trastuzumab in an adjuvant or palliative regimen.
|
25983297 |
2015 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Post-transcriptional loss of Nrdp1 in patient breast tumors allows ErbB3 overexpression and receptor contribution to tumor progression, and elevated lability through autoubiquitination contributes to the observed loss of Nrdp1 in tumors relative to normal tissue.
|
24519943 |
2014 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
A strong statistical correlation between NTS-NTSR1-and HER3 (p< 0.0001) as well as NTS-NTSR1-and HER3- HER2 (p< 0.001) expression was found in human breast tumors.
|
25249538 |
2014 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
Using the VeraTag® assay platform, we developed a dual antibody proximity-based assay for the precise quantitation of HER3 total protein (H3T) from formalin-fixed paraffin-embedded (FFPE) breast tumors.
|
23959396 |
2013 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Treatment of clinical breast tumors with the antiendocrine drug fulvestrant resulted in increased ErbB3 expression and PI3K/mTOR signaling.
|
23999432 |
2013 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
BEFREE |
These results may have important translational implications for the treatment and prevention of HER2-amplified breast tumors through ErbB3 inhibition.
|
22461506 |
2012 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
CTD_human |
In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer.
|
21638049 |
2012 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
This novel interaction may have clinical relevance, as immunohistochemical analysis of a small ER+ breast tumour series revealed significant positive correlations between phosphorylated IRS-1 Y612 expression and total erbB3, phosphorylated Akt and Ki-67 expression.
|
21939528 |
2011 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Analysis of a panel of human breast cancer cell lines (n = 50) and primary human breast tumors (n = 15) showed a strong positive correlation between ZNF217 and ErbB3 expression.
|
20661224 |
2010 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
LHGDN |
Evaluation of the prognostic and predictive value of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) study.
|
18985033 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
A central role for HER3 in HER2-amplified breast cancer: implications for targeted therapy.
|
18632642 |
2008 |
Mammary Neoplasms
|
0.500 |
Biomarker
|
group |
LHGDN |
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
|
18625725 |
2008 |
Mammary Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Compared to normal breast tissue, all four receptors were overexpressed in breast tumors and the strongest overexpression was found for HER-3 (p = 0.001).
|
17465220 |
2007 |